摘要
目的:分析增强剂量CTOP方案联合放疗治疗非何杰金氏淋巴瘤的疗效。方法:我院从2005年5月至2008年5月期间初治43例非何杰金氏淋巴瘤患者,随机分成对照组和观察组,分别采用常规剂量(THP40mg/m2)和增强剂量(THP60mg/m2)CTOP方案治疗6-8个疗程,第4-6个疗程后放疗一次,观察疗效及不良反应。结果:对照组总有效率(CR+PR)为81.82%,观察组的总有效率(CR+PR)为85.71%,疗效有所提高。两组毒副作用差异无显著性。结论:增强剂量CTOP方案结合放疗治疗非何杰金氏淋巴瘤有较好的疗效,与常规剂量CTOP方案相比毒副作用相仿。
Objective： To evaluate the efficacy of escalated CTOP regimen and radiotherapy in the treatment of non-Hodgking lymphoma （NHL）. Methods： 43 patients with NHL were divided into 2 groups randomly： group A with conventional CTOP regimen （n=22, THP 40 mg/m2） and group B with escalated CTOP regimen （n=21, THP 60 mg/m2） 6-8 times. The radiotherapy was taken on after 4-6 courses of treatment. The efficacy and the side effect were estimated. Results： The overall response （OR） rates were 85.71% （CR＋PR） in group B while 81.82% in group A. The side effect of the group B and group A were similar＇. There was no significant differ- ence between the two protocols. Conclusions： Together with radiotherapy, escalated CTOP Fegimen has better effect than conventional C TOP regimen in the treatment of NHL with n0 increase of the side effects.
出处
《现代生物医学进展》
CAS
2009年第12期2287-2289,共3页
Progress in Modern Biomedicine
